adenovirus-5 encoding human adenylyl cyclase type 6

Gene therapyexperimental

Clinical trial activity

2 trials · 8 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
2
Phase 3
1
Phase 4
0

Earliest trial started Jul 1, 2010 (NCT00787059)

Timeline

2010s

  1. Jan 1, 2010

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2018

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • ad5.hac6

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT03360448Phase 3Sep 30, 2018Renova Therapeutics
NCT00787059Phase 1/Phase 2 (Phase 2)Jul 1, 2010Minneapolis Heart Institute, National Heart, Lung, and Blood Institute (NHLBI), Northwestern University, Renova Therapeutics, University of California, San Diego, University of Utah, University of Vermont, University of Wisconsin
Showing 2 of 2 trials
Page 1 / 1

Organizations

Research & Development (8)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Renova TherapeuticsFor profit2122010
Minneapolis Heart InstituteAcademic/Hospital1012010
National Heart, Lung, and Blood Institute (NHLBI)Government1012010
Northwestern UniversityAcademic/Hospital1012010
University of California, San DiegoAcademic/Hospital1112010
University of UtahAcademic/Hospital1012010
University of VermontAcademic/Hospital1012010
University of WisconsinAcademic/Hospital1012010
8 organizations
Page 1 / 1